



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 14, 2021

Paul Averbach
Chief Executive Officer
NYMOX PHARMACEUTICAL CORP
Bay & Deveaux Streets
Nassau, The Bahamas

Re: NYMOX PHARMACEUTICAL CORP
Registration Statement on Form F-3
Filed May 12, 2021
File No. 333-256024

Dear Dr. Averbach:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tom Kluck at 202-551-3233 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: M. Richard Cutler